Programmed death-ligand 1 immunoexpression in matched biopsy and liquid-based cytology samples of advanced stage non-small cell lung carcinomas
Author:
Affiliation:
1. Department of Pathology; All India Institute of Medical Sciences; New Delhi India
2. Department of Pulmonary Medicine & Sleep Disorders; All India Institute of Medical Sciences; New Delhi India
Funder
All-India Institute of Medical Sciences
Publisher
Wiley
Subject
General Medicine,Histology,Pathology and Forensic Medicine
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1111/cyt.12605/fullpdf
Reference36 articles.
1. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer;Brahmer;N Engl J Med,2015
2. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer;Borghaei;N Engl J Med,2015
3. U.S. FDA approval summary: nivolumab for treatment of unresectable or metastatic melanoma following progression on ipilimumab;Hazarika;Clin Cancer Res,2017
4. Atezolizumab, an anti-programmed death-ligand 1 antibody, in metastatic renal cell carcinoma: long-term safety, clinical activity, and immune correlates from a Phase Ia Study;McDermott;J Clin Oncol,2016
5. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer;Reck;N Engl J Med,2016
Cited by 38 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Principles of Analytic Validation of Immunohistochemical Assays: Guideline Update;Archives of Pathology & Laboratory Medicine;2024-02-23
2. The detection of PD‐L1 expression on liquid‐based cytology in pleural effusion of lung adenocarcinoma and its prognostic evaluation: Between paired liquid‐based cytology and cell block samples;Diagnostic Cytopathology;2024-01-23
3. Assessing PD-L1 Expression in Different Tumor Types;Handbook of Cancer and Immunology;2023
4. Expression of PD-L1 in Lung Carcinoma and Its Correlation with Histopathological Grade, Stage, and Survival of Patients;Journal of Laboratory Physicians;2022-12-05
5. PD-L1 assessment in cytology samples predicts treatment response to checkpoint inhibitors in NSCLC;Lung Cancer;2022-09
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3